Neopharmed Gentili Acquires European Business of BioCryst Pharmaceuticals
Deal News | Jul 02, 2025 | Legal Community Italy
Neopharmed Gentili, an Italian pharmaceutical company controlled by the Del Bono family alongside private equity firms Ardian and Renaissance Partners, has entered into an agreement to acquire the European business segment of BioCryst Pharmaceuticals focusing on the drug ORLADEYO (berotralstat), used for the treatment of rare diseases. The transaction is expected to close by October 2025, with an initial consideration of $250 million, plus a potential additional $14 million contingent on achieving specific commercial milestones. This strategic acquisition aims to strengthen Neopharmed Gentili's position in the high-growth rare disease segment within the European pharmaceutical market. White & Case LLP advised Neopharmed Gentili on legal aspects, including M&A, intellectual property, taxation, regulatory, antitrust, and financing arrangements. Centerview Partners UK acted as the financial advisor, PwC TLS handled tax due diligence, and Linklaters represented the financiers.
Sectors
- Pharmaceuticals
- Private Equity
- Legal Services
Geography
- Italy – Neopharmed Gentili, the acquiring company, is based in Italy and plays a central role in the transaction.
- United States – BioCryst Pharmaceuticals, the vendor in the transaction, is based in the United States, reflecting international investment dynamics.
- European Union – The acquisition targets the European business segment of BioCryst, highlighting a focus on the European pharmaceutical market.
Industry
- Pharmaceuticals – The acquisition involves BioCryst Pharmaceuticals' business related to ORLADEYO, a pharmaceutical product for rare diseases, directly linking the article to the pharmaceutical industry.
- Private Equity – Private equity firms, Ardian and Renaissance Partners, are key stakeholders in Neopharmed Gentili, indicating the involvement of private equity in the transaction.
- Legal Services – The transaction involves extensive legal advisory services, including M&A, intellectual property, antitrust, taxation, and regulatory, provided by White & Case LLP.
Financials
- 250,000,000 – Initial consideration for the acquisition of BioCryst’s European business segment.
- 14,000,000 – Potential additional payment contingent on achieving specific commercial milestones.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neopharmed Gentili | Target Company | Company | An Italian pharmaceutical company involved in acquiring BioCryst Pharmaceuticals' European business for ORLADEYO. |
| BioCryst Pharmaceuticals | Selling Company | Company | The company selling its European business related to ORLADEYO, a treatment for rare diseases. |
| Ardian | Private Equity Firm | Company | A private equity firm that partially controls Neopharmed Gentili and supports its acquisition strategy. |
| Renaissance Partners | Private Equity Firm | Company | A private equity firm that, alongside Ardian, controls Neopharmed Gentili. |
| White & Case LLP | Legal Advisor | Company | Provided comprehensive legal advisory services to Neopharmed Gentili on the acquisition. |
| Centerview Partners UK | Financial Advisor | Company | Acted as the financial advisor for Neopharmed Gentili in the acquisition process. |
| PwC TLS | Tax Advisor | Company | Handled tax due diligence and structuring for the acquisition. |
| Linklaters | Financier's Legal Advisor | Company | Assisted the financiers with legal advice on the transaction. |